BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study

BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study

Source: 
Investors Business Daily
snippet: 

BridgeBio Pharma (BBIO) smashed Wall Street's expectations in a study of children with dwarfism, leading BBIO stock to break out in massive volume.